B7-H1 Antigen

An inhibitory B7 antigen that contains V-type and C2 type immunoglobulin domains. It has specificity for the T-CELL receptor PROGRAMMED CELL DEATH 1 PROTEIN and provides negative signals that control and inhibit T-cell responses. It is found at higher than normal levels on tumor cells, suggesting its potential role in TUMOR IMMUNE EVASION.

Also Known As:

B7-H1 Immune Costimulatory Protein; B7H1 Immune Costimulatory Protein; CD274 Antigen; PD-L1 Costimulatory Protein; Programmed Cell Death 1 Ligand 1; Antigen, B7-H1; Antigen, CD274; B7 H1 Antigen; B7 H1 Immune Costimulatory Protein; CD274 Antigens; Costimulatory Protein, PD-L1; PD L1 Costimulatory Protein; PD L1 Protein; Antigens, CD274; PD-L1 Protein; Programmed Cell Death 1 Ligand 1 Protein; Programmed Death Ligand 1

Networked: 4096 relevant articles (301 outcomes, 519 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Oda, Yoshinao: 30 articles (01/2022 - 01/2015)
2.	Rimm, David L: 22 articles (10/2022 - 01/2014)
3.	Freeman, Gordon J: 22 articles (01/2021 - 09/2007)
4.	Reck, Martin: 21 articles (01/2022 - 11/2016)
5.	Maehara, Yoshihiko: 21 articles (12/2019 - 01/2015)
6.	Powles, Thomas: 19 articles (01/2022 - 11/2014)
7.	Takada, Kazuki: 17 articles (01/2022 - 07/2016)
8.	Takamori, Shinkichi: 17 articles (01/2021 - 07/2016)
9.	Hirsch, Fred R: 16 articles (01/2022 - 07/2015)
10.	Okamoto, Tatsuro: 16 articles (01/2021 - 01/2016)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2023 - "Currently, the most clinically relevant bio-markers used to predict efficacy of ICIs in patients with advanced TNBC remain the immunohistochemical analysis of programmed death-ligand 1 (PD-L1) expression, the assessment of tumor infiltrating lymphocytes (TILs) present in the tumor microenvironment (TME), and the evaluation of the tumor mutational burden (TMB). " 07/01/2020 - "The combination with programmed death-ligand 1 blockade led to potent therapeutic efficacy which exhibited increased tumor-infiltrating CD8 T cells. " 12/01/2018 - "Programmed death 1/programmed death ligand 1 (PD-L1) axis inhibitors have been proven effective, especially in patients with tumors expressing PD-L1. " 01/01/2023 - "The combination of AGK2 and programmed death ligand 1 (PD-L1) blockade effectively suppressed tumor growth and improved overall survival of mice. " 01/01/2019 - "Outcomes included pooled PD-L1 protein positivity in tumor cells, immune cells, or both, per subtype and per antibody used, and its prognostic value for disease-free and overall survival. "
2.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 06/01/2021 - "We analyzed the prognostic efficacy of programmed death-ligand 1 (PD-L1) in locally advanced non-small cell lung cancer (LA-NSCLC) patients. " 01/01/2023 - "In the non-small-cell lung cancer (NSCLC) trial subset, we observed a negative association between treatment effects on overall grade 1-2 irAEs and treatment effects on OS in studies with patients selected for programmed death-ligand 1 expression (R2 = 0.55; 95% confidence interval 0.20-0.95; R = -0.69). " 11/16/2022 - "This study aims to investigate the correlation between intravoxel incoherent motion diffusion-weighted imaging (IVIM-DWI) parameters in magnetic resonance imaging (MRI) and programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer (NSCLC). " 05/01/2022 - "Aim To study the prevalence of programmed death-1 receptor (PD-1) and programmed death-ligand 1 (PD-L1) positive cases in non-small-cell lung carcinoma (NSCLC) and their association with other clinicopathological parameters in a tertiary care setting in North India. " 03/01/2022 - "Due to some interconnectedness at the molecular level, this study assessed the possible influence of laboratory parameters associated with systemic inflammatory environment on programmed death-ligand 1 (PD-L1) expression in non-small cell lung carcinoma (NSCLC). "
3.	Melanoma (Melanoma, Malignant) 01/01/2023 - "Continuous combination of MAPK pathway inhibition (MAPKi) and anti-programmed death-(ligand) 1 (PD-(L)1) showed high response rates, but only limited improvement in progression-free survival (PFS) at the cost of a high frequency of treatment-related adverse events (TRAE) in patients with BRAFV600-mutated melanoma. " 06/01/2022 - "The aim of this multicentre study was to harmonize programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) and melanoma scoring. " 01/01/2021 - "Although clinical studies have shown the potential of targeting programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) signaling in melanoma, response rates are low. " 01/01/2019 - "The aim of this study is to determine the significance of programmed death ligand 1 (PD-L1 or CD274) methylation in relation to PD-L1 expression and survival in melanoma. " 01/01/2023 - "ULK1 binds IRF1 in the nuclear compartment of melanoma cells, controlling its binding to the programmed death-ligand 1 promoter region. "
4.	Lung Neoplasms (Lung Cancer) 01/01/2023 - "Our study also verified that the expression level of immune checkpoints-related molecule Programmed Death-Ligand 1 (PD-L1) (P = 0.0002) and the density of tumor-infiltrating lymphocytes (TILs) (P = 0.0248) in BMs were significantly lower than that in paired primary lung cancers. " 01/01/2021 - "The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC." 11/01/2017 - "In present study, we evaluated the metabolic characteristics of lung cancer by using 18 F-fluorodeoxyglucose positron emission tomography/computed tomography (18 F-FDG PET/CT) with regard to PD-L1 protein expression. " 08/01/2023 - "It has been reported that programmed cell death 1 ligand 1 (PD-L1) and tumor-associated macrophages are closely related to the development of lung cancer. " 08/01/2023 - "Additionally, Cin upregulated programmed death-ligand 1 (PD-L1) expression in lung cancer cells by inhibiting autophagy. "
5.	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/01/2023 - "Retracted: The Change of Soluble Programmed Death Ligand 1 (sPD-L1) in Plasma of Small Cell Lung Cancer and Its Clinical Significance." 01/01/2022 - "The Change of Soluble Programmed Death Ligand 1 (sPD-L1) in Plasma of Small Cell Lung Cancer and Its Clinical Significance." 12/01/2019 - "Characterization of PD-L1 protein expression and CD8+ tumor-infiltrating lymphocyte density, and their associations with clinical outcome in small-cell lung cancer." 03/23/2019 - "Objective: To explore the correlation between programmed death ligand 1 (PD-L1) expression and clinicopathological features and prognosis of small cell lung cancer (SCLC). " 12/20/2018 - "【中文题目：晚期非小细胞肺癌免疫治疗的一线联合治疗】【中文摘要：程序性细胞死亡分子1/配体1（programmed death 1/programmed death ligand 1, PD-1/PD-L1）抑制剂已成为晚期非小细胞肺癌（non-small cell lung cancer, NSCLC）重要治疗手段之一。目前已有一部分NSCLC患者可以接受PD-1抑制剂单药作为一线免疫肿瘤治疗（immuno-oncology，IO，又简称免疫治疗），但应用时的诸多限制使可成为IO一线单药治疗候选者的人群有限。使IO一线治疗可让更广人群的更多获益，多项研究正聚焦于IO与其他药物在NSCLC中的联合应用。本文回顾了近年来IO一线联合治疗的最新临床数据，提示在PD-1/PD-L1抑制剂的基础上，联合其他IO、化疗、抗血管生成药物、靶向治疗或放疗可能产生抗肿瘤协同效应，有望使更多初治患者获益。 】【中文关键词：程序性死亡分子1/程序性死亡配体1抑制剂；肺肿瘤；一线联合；免疫肿瘤治疗】."

Related Drugs and Biologics

1.	Immune Checkpoint Inhibitors
2.	pembrolizumab
3.	Programmed Cell Death 1 Receptor
4.	atezolizumab
5.	Platinum
6.	Nivolumab
7.	Monoclonal Antibodies
8.	Proteins (Proteins, Gene)
9.	Biomarkers (Surrogate Marker)
10.	Antibodies

Related Therapies and Procedures

1.	Immunotherapy
2.	Therapeutics
3.	Drug Therapy (Chemotherapy)
4.	Radiotherapy
5.	Chemoradiotherapy